HIV screening urged for everyone aged 15 to 65 in U.S. | Experimental myeloma drug aids survival in trial | Blood-clot detection trial begins for inhaled gas
Web Version
 
 
November 20, 2012
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
HIV screening urged for everyone aged 15 to 65 in U.S.
The U.S. Preventive Services Task Force on Monday called for routine HIV testing for all Americans aged 15 to 65, expanding its 2005 recommendation that included only high-risk individuals. The draft recommendation was prompted by studies showing major health benefits of early HIV treatment, task force chairwoman Dr. Virginia Moyer said. USA Today (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Announcing the Arrival of FMH RapidScreen from Immucor
The new FMH RapidScreen offers a faster more simplified feto-maternal hemorrhage screening test to give you peace of mind in generating a quick result for the protection of mothers and their newborns. FMH RapidScreen provides up to 35% decrease in total test time compared to other marketed tests. To learn more about this product, call us at 855-IMMUCOR or visit our website.
Advertisement
 
Science & Health
Experimental myeloma drug aids survival in trial
Patients with multiple myeloma who received Celgene's pomalidomide plus low-dose dexamethasone lived significantly longer and had greater progression-free survival than those who received high-dose dexamethasone alone during a trial. An FDA review of the drug is expected to be completed by Feb. 10. Reuters (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Blood-clot detection trial begins for inhaled gas
Cyclopharm has the first patient for a U.S. study of Technegas, which is inhaled to improve the detection of blood clots in the lungs during imaging tests. The multi-center study will involve 750 patients and could be completed in 18 months. ProactiveInvestors.co.au (Australia) (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
StemCyte, UC Davis partner for public cord blood banking
The Umbilical Cord Blood Collection Program at the University of California, Davis, and StemCyte will work together on the public banking of cord blood cells. During the first six months, the partners will work on speeding collection of cord blood donations to benefit people with life-threatening conditions. Genetic Engineering & Biotechnology News (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
Living Cell Technologies to start human Ntcell trial
New Zealand's health regulators have given the go-ahead for Living Cell Technologies' early-stage clinical study of its Ntcell treatment for Parkinson's disease. The first human trial for the treatment is slated to start early next year. The therapy includes the transplantation of animal choral plexus cells into the brain to restore nerves. Australian Life Scientist (11/16)
Share: LinkedInTwitterFacebookGoogle+Email
Hospitals have until Nov. 30 to attest to MU for FY 2012
To receive payments from the Medicare EHR incentive program for fiscal 2012, hospitals must register and attest to meaningful use by the end of the month. All facilities are encouraged to enroll prior to the Nov. 30 deadline, particularly those planning to attest for FY 2012. BeckersHospitalReview.com (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
FDA OKs use of platelet drug to help hepatitis C patients
The FDA approved GlaxoSmithKline and Ligand Pharmaceuticals' eltrombopag to treat low platelet count in people with hepatitis C so they can receive standard treatment. The approval is the first for supportive care to help patients unsuited for interferon-based therapy because of low platelet counts. Reuters (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
FDA gives OK to Mesoblast for mesenchymal precursor cell production
Mesoblast and the FDA have reached an agreement regarding the production process for mesenchymal precursor cells to be used in late-stage clinical trials for the treatment of congestive heart failure and other conditions. The FDA and Mesoblast put in place a path for the possible commercial production of the company's cell therapy products. Australian Life Scientist (11/20)
Share: LinkedInTwitterFacebookGoogle+Email
EU supports approval of iron overload treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use has backed Novartis' Exjade as a treatment for chronic iron overload requiring chelation among patients ages 10 and up with non-transfusion-dependent thalassemia syndromes who do not respond to deferoxamine. Pharmaceutical Business Review Online (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
AABB requests nominations for 2013, 2014 Memorial Awards
AABB is seeking nominations for its 2013 and 2014 Memorial Awards, which will honor individuals who have advanced the practice of transfusion medicine and cellular therapies. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form by Jan. 25. Recipients will be honored at the 2013 AABB Annual Meeting in Denver or the 2014 AABB Annual Meeting in Philadelphia.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Help Desk SpecialistAABBUS - MD
Click here to view more job listings.
 
SmartQuote
A good man with a good conscience doesn't walk so fast."
-- Georg Büchner,
German writer
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information